Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266313 | 1.00 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL22266278 | 0.98 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL22266320 | 0.93 | CYP1A2 (0.32) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL22266268 | 0.90 | CYP1A2 (0.30) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL22266258 | 0.87 | TSHR (0.34) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL22266264 | 0.86 | TSHR (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22266238 | 0.85 | GAA (0.33) | GAA | |
| SCHEMBL22266280 | 0.83 | CYP1A2 (0.30) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22297251 | 0.83 | CYP1A2 (0.33) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL20324175 | 0.83 | CYP1A2 (0.33) | HDAC3HDAC1HDAC2HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | HDAC3 4037/4885HDAC1 3130/4885HDAC2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.